Exicure, Inc.

XCUR

US30205M2008

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-22 EDT			5-day change	1st Jan Change
0.4651 ^USD	-1.88%		-6.98%	-19.85%

05-16	Exicure, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
03-22	North American Morning Briefing : Stocks Struggle After New Records	DJ

Presenter SpeechThomas Hoffmann (Executives)Hi, everyone, and welcome to Solebury Trout's Fift...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about Exicure, Inc.

Exicure, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	05-16	CI
North American Morning Briefing : Stocks Struggle After New Records	03-22	DJ
An unknown buyer agreed to acquire 39.3% stake in Exicure, Inc. from DGP Co.,Ltd. for KRW 6 billion.	02-28	CI
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis	02-05	CI
Wall Street Set to Open Lower Friday; Employment Growth Tops Forecasts	12-08	MT
Investors Look Ahead to Economic Indicators as US Futures Trend Lower in Friday's Premarket	12-08	MT
Top Premarket Gainers	12-08	MT
Northwestern University Notifies Exicure, Inc. that it Was Terminating the 2014 License	23-10-06	CI
Exicure, Inc. Appoints Minhee Eom to the Board	23-09-27	CI
Exicure Appoints New CEO, CFO	23-08-23	MT
Exicure, Inc. Announces Executive Changes	23-08-23	CI
Exicure, Inc. Announces Chief Financial Officer Changes	23-08-23	CI
Exicure, Inc. Announces Executive Changes	23-08-23	CI
Exicure Inc Provides Information to Shareholders	23-08-23	CI
North American Morning Briefing : China Trouble Hits Sentiment	23-08-18	DJ
Exicure, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
CBI Co Provides Information to Shareholders of Exicure Inc	23-08-08	CI
Exicure, Inc. Announces Resignation of Cheolho Jo from the Board and the Audit Committee	23-08-04	CI
Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-07-14	CI
North American Morning Briefing : Recession Threat Grows as Further Tightening Likely	23-06-23	DJ
North American Morning Briefing : Stock Futures -2-	23-06-16	DJ
North American Morning Briefing : Caution Ahead of Fed, Inflation Data to Hold Back Stocks	23-06-09	DJ
North American Morning Briefing : Stock Futures -2-	23-06-02	DJ
Exicure, Inc. Appoints Jung Sang as Chief Financial Officer	23-05-29	CI
Exicure, Inc. Appoints Jung Sang Kim as Chief Executive Officer	23-05-29	CI

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is developing nucleic acid therapies targeting ribonucleic acid (RNA) to address both genetic and non-genetic neurological disorders. Its lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A. It is engaged in discovery efforts across a range of indications and therapeutic targets, such as pain using non-opioid analgesics, as well as rare neurological genetic disorders, including Huntington's disease, Angelman Syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis (ALS). The Company focuses on pursuing out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
EXICURE, INC.	-19.85%	4.02M
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	115B
REGENERON PHARMACEUTICALS, INC.	+12.01%	106B
BIONTECH SE	-3.07%	24.69B
ARGENX SE	-0.76%	21.97B
GENMAB A/S	-4.78%	19.27B
BEIGENE, LTD.	-6.90%	17.56B
WUXI APPTEC CO., LTD.	-39.36%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+5.82%	14.03B
SAREPTA THERAPEUTICS, INC.	+33.05%	12.13B